BioAtla Inc logo

BCAB

BioAtla Inc

$9.56

Earnings Summary

Revenue
$0Mn
Net Profits
$-24.25Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

BioAtla Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2022. On a quarterly growth basis, BioAtla Inc has generated -100% fall in its revenue since last 3-months.

Net Profits:

BioAtla Inc’s net profit fell -29.69% since last year same period to $-24.25Mn in the Q1 2022. On a quarterly growth basis, BioAtla Inc has generated -3.69% fall in its net profits since last 3-months.

Net Profit Margins:

BioAtla Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2022. On a quarterly growth basis, BioAtla Inc has generated -Inf% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the BioAtla Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.69
EPS Estimate Current Year
-0.69

Highlights

EPS Estimate Current Quarter:

BioAtla Inc’s earning per share (EPS) estimates for the current quarter stand at -0.69 - a -2.99% fall from last quarter’s estimates.

EPS Estimate Current Year:

BioAtla Inc’s earning per share (EPS) estimates for the current year stand at -0.69.

Key Ratios

Key ratios of the BioAtla Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.65
Return on Assets (ROA)
-0.29
Return on Equity (ROE)
-0.58
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

BioAtla Inc’s earning per share (EPS) fell -16.07% since last year same period to -0.65 in the Q1 2022. This indicates that the BioAtla Inc has generated -16.07% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. BioAtla Inc’s return on assets (ROA) stands at -0.29.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. BioAtla Inc’s return on equity (ROE) stands at -0.58.

Dividend Per Share (DPS):

BioAtla Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-05
-0.67
-0.65
2.99%

Company Information

BioAtla® is a San Diego biotech company that develops novel monoclonal antibody and cell based therapeutics using our proprietary Conditionally Active Biologics™ (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!™) platforms. These and other proprietary technologies (protected by more than 150 issued patents and patent applications) allow it to develop novel biologics (CABs) that are better drugs in multiple ways including more selective targeting of cancer tissue and improved manufacturability. Improved selectivity for the tumor microenvironment (TME), even when the target is also found in normal tissue, not only improves safety and thus therapeutic index but also expands the universe of potential drug targets, enabling the treatment of previously untreatable cancers.

Organisation
BioAtla Inc
Employees
36